These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10742710)

  • 21. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M
    Heart Fail Monit; 2002; 2(3):85-7. PubMed ID: 12634889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
    Pitt B; Poole-Wilson P; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
    J Card Fail; 1999 Jun; 5(2):146-54. PubMed ID: 10404354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure].
    Latini R
    Ital Heart J Suppl; 2001 Jan; 2(1):83-4. PubMed ID: 11216088
    [No Abstract]   [Full Text] [Related]  

  • 25. [A-II blocker or ACE inhibitor in heart failure? Captopril can't be beat].
    Einecke D
    MMW Fortschr Med; 1999 Nov; 141(47):4-5. PubMed ID: 10912155
    [No Abstract]   [Full Text] [Related]  

  • 26. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
    Eisenstein EL; Nelson CL; Simon TA; Smitten AL; Lapuerta P; Mark DB
    Am Heart J; 2002 Jun; 143(6):1112-7. PubMed ID: 12075271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent clinical trials with omapatrilat: new developments.
    Zanchi A; Maillard M; Burnier M
    Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II type 1 receptor blockers and congestive heart failure.
    Auer JW; Berent R; Eber B
    Circulation; 2001 Oct; 104(15):E82. PubMed ID: 11591633
    [No Abstract]   [Full Text] [Related]  

  • 29. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors].
    Berger D
    Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712087
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of losartan and captopril in ELITE II.
    Lye M
    Lancet; 2000 Sep; 356(9232):852; author reply 852-3. PubMed ID: 11022949
    [No Abstract]   [Full Text] [Related]  

  • 32. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
    Dickstein K
    Am Heart J; 2003 May; 145(5):754-7. PubMed ID: 12766730
    [No Abstract]   [Full Text] [Related]  

  • 33. ACE inhibitors still the drug of choice for heart failure--and more.
    Topol E
    Lancet; 1999 Nov; 354(9192):1797. PubMed ID: 10577651
    [No Abstract]   [Full Text] [Related]  

  • 34. [Heart failure and vasopeptidase inhibitors].
    Bareiss P; Ohlmann P; Roul G
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current role of angiotensin II antagonists in the treatment of heart failure].
    Porcu M; Orrù P
    Ital Heart J Suppl; 2000 Sep; 1(9):1213-4. PubMed ID: 11140296
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of heart failure: an update].
    Sinagra G; Perkan A; Cherubini A; Salvatore L; Di Lenarda A
    Ital Heart J Suppl; 2002 Jul; 3(7):691-7. PubMed ID: 12187629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of losartan and captopril in ELITE II.
    Hall A
    Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022946
    [No Abstract]   [Full Text] [Related]  

  • 38. Early and chronic captopril or Losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats.
    Martínez LA; Villalobos-Molina R
    Arch Med Res; 2003; 34(5):357-61. PubMed ID: 14602500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
    Konstam MA; Neaton JD; Poole-Wilson PA; Pitt B; Segal R; Sharma D; Dasbach EJ; Carides GW; Dickstein K; Riegger G; Camm AJ; Martinez FA; Bradstreet DC; Ikeda LS; Santoro EP;
    Am Heart J; 2005 Jul; 150(1):123-31. PubMed ID: 16084158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
    Martineau P; Goulet J
    Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.